Do You Need a License to Sell Peptides in Michigan?

There is no single, standalone "peptide license" that a business applies for and receives. What actually determines your obligations is the shape of your business — whether you are simply operating a registered company, whether your model puts you into the category of a drug or device distributor, and whether you are handling research-use-only material and representing it accurately. Those are three separate questions with three separate answers, and only one of them is about peptides at all. This article is informational and is not legal advice; the specifics for your operation belong with a Michigan-licensed attorney and, where relevant, your state board.

Three separate questions hiding inside one

Operators tend to search for licensing as if it were a single yes-or-no gate. It is not. Untangling it into three questions makes the path far clearer.

Question one is ordinary business formation. Any company that sells anything generally needs to exist as a legal entity, register with the state, handle sales tax where applicable, and maintain whatever local permits its municipality requires. This has nothing to do with peptides specifically. Your accountant and your formation attorney handle it, and it is the least interesting part of the analysis — but it is also the part people skip when they start selling out of an existing wellness business without amending anything.

Question two is whether your model triggers drug or device distribution licensing. Most states maintain licensing categories for wholesale drug distributors, and pharmacy boards typically administer them. Whether a given product and a given transaction fall inside those categories is a legal determination that turns on how the material is characterized, what it is labeled for, and what the seller represents about it. Do not assume you are outside that category because the compound is sold for laboratory work, and do not assume you are inside it because the word "peptide" sounds clinical. Ask your attorney directly: given exactly what I intend to sell, to whom, and with what labeling, does my state's board consider this activity licensable distribution? That is the question with a real answer.

Question three is whether your representations match your product. Research-use-only material carries labeling and framing obligations that follow it through the whole chain. A supplier can label correctly and a downstream reseller can still create a problem by describing the same vial in marketing copy as something it is not. This is the failure mode that catches otherwise careful businesses, and it is entirely within your control.

What state boards actually regulate, and what they do not

Regulatory bodies do not generally license molecules. They license activities and the people who perform them. A pharmacy board is concerned with dispensing and distribution. A medical board is concerned with the scope of practice of licensed clinicians. A department of agriculture or a state health department may have jurisdiction over labeling and product claims. None of these bodies publishes a tidy "peptides" chapter you can read in an afternoon.

That structural fact should change how you research. Instead of searching for a rule that names your product, describe your intended activity in plain language and ask which existing category it lands in. A useful framing for counsel:

• I intend to purchase bulk research-use-only material from a wholesale supplier and resell it in original or repackaged form.
• My customers are [businesses / laboratories / other resellers], and here is how I verify who they are.
• My labeling says the following, and my website says the following.
• Given all of that, which state and federal categories apply to me, and what registrations follow?

An attorney can answer that. A blog post cannot, and any page that tells you flatly that a particular state permits or forbids resale — without knowing your model — is guessing on your behalf. In most states the answer varies with the details, and the details are yours.

Where the research-use-only lane begins and ends

Research-use-only is not a loophole; it is a description of what the material is and what it is not. Compounds supplied on this basis are not FDA-approved drugs, are not intended for human consumption, and are not supplied with dosing or administration guidance. The framing has to be consistent everywhere the product appears: purchase order, packing slip, vial label, product page, and every piece of marketing you or your staff produce.

The boundary is crossed by language more often than by logistics. Describing a compound in terms of what it does for a person, publishing suggested amounts, bundling it with administration supplies in a way that implies a use kit, or letting a sales conversation drift into outcomes — each of these changes the character of the transaction regardless of what the label says. If you are building a catalog, the discipline is to write about the compound science and the sourcing, and to stop there. Where research is worth mentioning, hedge it honestly: studies indicate, research suggests, preliminary work has examined. Never a promise.

This also shapes who you can responsibly sell to. Suppliers that verify buyers are not adding friction for its own sake — they are keeping research material inside a research channel. A supplier that sells to anyone with a credit card is telling you something about how it manages the same risk you are about to inherit.

Questions to resolve before you stock anything

Before a first purchase order, work through this list with counsel rather than with a forum thread:

• Which entity is buying, and does that entity's registration and insurance actually cover this activity?
• Does my intended activity fall within any wholesale distribution licensing category in my state, and if the answer is uncertain, who at the board can be asked in writing?
• Do I intend to repackage, relabel, or aliquot? Repackaging almost always raises the regulatory stakes compared with reselling sealed units, so treat it as a distinct decision.
• How will I verify that my buyers are legitimate businesses, and what record of that verification will I keep?
• What does my marketing copy say today, and would it survive being read aloud to a regulator?
• What are my documentation obligations for lot traceability, and can my supplier support them?

None of those questions have a universal answer. All of them have an answer for your business, and getting them settled early is cheaper than getting them settled later.

How a wholesale supplier qualifies a business buyer

Qualification runs in both directions. You are evaluating a supplier, and a serious supplier is evaluating you. Expect to identify your business, describe what you intend to stock, and confirm you understand the research-use-only terms. That intake is the supplier's own compliance work, and it is a reasonable proxy for how the rest of the operation is run.

On your side of the table, the evaluation is about evidence rather than assurances. The industry has well-known bad habits: pricing that only appears after a sales call, certificates of analysis that are withheld or sold as an add-on, and testing described in general terms with no document behind it. Each of those is a signal, and none of them is subtle once you know to look.

What to verify before a first order

What Real Peptides does differently

Real Peptides supplies research-use-only peptides to businesses through its Wholesale Partner Program, and the program is built around evidence a buyer can check independently rather than claims a buyer has to accept.

Compounds are supplied at 99%+ HPLC purity. Every batch goes through six-panel testing rather than a single spot check, so identity and contamination questions are addressed alongside purity. The resulting certificates of analysis are publicly verifiable — a prospective partner can read the lab results before applying, without a sales call and without paying for the document. That is the part worth pausing on, because the common industry practice of treating a COA as a gated asset is precisely what prevents a buyer from doing the diligence this article recommends.

Fulfillment is handled from within the United States, with orders typically moving in five to seven days, which removes the customs and transit uncertainty that comes with sourcing overseas. Wholesale pricing is tiered and disclosed, not negotiated in the dark. And the application itself is a three-step process rather than an extended sales cycle: submit your business information, get reviewed, and receive tier pricing.

What Real Peptides does not do is equally relevant. Compounds are never framed as human therapeutics, never supplied with dosing or administration guidance, and never bundled with supplies in a way that implies a use kit. A supplier that holds that line makes it materially easier for you to hold it too.

Where to go from here

If you have worked through the licensing questions with your own counsel and you know which lane your business operates in, the next step is sourcing that can survive the same scrutiny. Businesses that are ready to stock research-use-only material can submit their information through the Wholesale Partner Program and review the published lab results first — in that order, ideally, since the documentation is what the rest of your compliance position rests on.

For more on program structure and how to get qualified, see the wholesale peptides program overview, read the general framework on do you need a license to sell peptides, or apply for a wholesale account when your entity and documentation are in order.